2025-12-28 - Analysis Report
Here's a comprehensive analysis of Merck & Co. (MRK) based on the provided data:

**0) Summary of Data:**

*   **Company Overview:** Merck & Co. is a global pharmaceutical company.
*   **Cumulative Return:** MRK: 27.02%, VOO: 103.21%
*   **Divergence:** -80.6 (Relative Divergence: 18.5)
*   **Recent Price:** $106.78
*   **Moving Averages:** 5-day SMA: 104.82, 20-day SMA: 101.29, 60-day SMA: 93.31
*   **RSI:** 71.04 (Overbought)
*   **PPO:** 0.31
*   **MRI:** 1.0 (High Investment Recommended)
*   **Expected Return:** -47.6% (Long-term, compared to S&P 500)
*   **Analyst Consensus:** Buy ($110.04 Target Price)

**1) Return Rate Comparison and Alpha/Beta Analysis:**

*   **Return Rate:** MRK's cumulative return of 27.02% significantly underperforms the S&P 500's return of 103.21%. This represents a divergence of -80.6, placing it in the lower end of its historical divergence range (Relative Divergence: 18.5).

*   **Alpha/Beta Analysis:**

    | Year       | CAGR   | MDD   | Alpha   | Beta  | Cap(B) |
    |------------|--------|-------|---------|-------|--------|
    | 2015-2017  | 1.0%   | 68.5% | -28.0%  | 0.0   | 134.1  |
    | 2016-2018  | 36.0%  | 69.8% | 21.0%   | -0.0  | 182.1  |
    | 2017-2019  | 40.0%  | 69.8% | 18.0%   | 0.3   | 216.8  |
    | 2018-2020  | 16.0%  | 79.6% | -8.0%   | 0.3   | 195.0  |
    | 2019-2021  | 2.0%   | 79.6% | -44.0%  | 0.7   | 191.4  |
    | 2020-2022  | 15.0%  | 79.6% | 16.0%   | 0.7   | 277.1  |
    | 2021-2023  | 33.0%  | 79.6% | 31.0%   | 0.3   | 272.3  |
    | 2022-2024  | -4.0%  | 79.6% | -25.0%  | 0.2   | 248.5  |
    | 2023-2025  | -22.0% | 71.5% | -90.0%  | 1.8   | 266.7  |

    *   **CAGR:** The Compound Annual Growth Rate shows fluctuating performance.  Recent periods (2022-2025) exhibit negative growth.
    *   **MDD:** High Maximum Drawdown percentages suggest significant volatility and potential for losses during specific periods.
    *   **Alpha:**  Alpha, representing performance relative to a benchmark, is largely negative, indicating underperformance compared to the market. The -90% Alpha for 2023-2025 is particularly concerning.
    *   **Beta:** Beta, measuring volatility relative to the market, is generally low but increases significantly in the most recent period (2023-2025). A Beta of 1.8 indicates that MRK's price is now more volatile than the overall market.
    *   **Cap(B):** The market capitalization of MRK shows an increasing trend during the given time, however, it decreased recently (2022-2024).

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** $106.78
*   **Moving Averages:** The rising moving averages (5-day > 20-day > 60-day) indicate a recent upward trend in the stock price. The price is above all three SMAs.

**3) RSI, PPO, and Expected Return Analysis:**

*   **MRI:** A Market Risk Indicator of 1.0 suggests a "High Investment Recommended" rating, which contradicts other negative indicators.
*   **RSI:** An RSI of 71.04 suggests the stock is currently overbought, potentially indicating a possible pullback in the near future.
*   **PPO:** A PPO of 0.31 indicates that the 12-period moving average is above the 26-period moving average, suggesting a short-term upward trend.
*   **Hybrid Signal:** The hybrid signal recommends buying 100% of available cash (2 shares), labeling it "Very Safe". This recommendation is driven by the high MRI, which should be viewed cautiously given other negative indicators.
*   **Relative Divergence Change:** A positive change of 1.3 in recent relative divergence suggests a short-term increase in the stock's performance compared to the S&P 500.
*   **Expected Return:** A significantly negative expected return of -47.6% compared to the S&P 500 over a long-term investment horizon is a major red flag.

**4) Recent News & Significant Events:**

*   The news articles present a mixed outlook:
    *   Positive: One article highlights an upgrade with a price target of $130 and MRK stock surge. "MRK Stock Surges 8.3% In A 6-day Winning Spree On BMO Upgrade To $130 - Trefis"
    *   Mixed: Other articles question the legitimacy of the stock's run and examine its overall health. "Is Merck Stockâ€™s Run Legitimate? - Forbes"
    *   Negative: Some articles report lowered stock holdings. "Merck & Co., Inc. $MRK Stock Holdings Lowered by Kempner Capital Management Inc. - MarketBeat"
    *   Dividend Increase: A dividend increase is generally a positive sign. "Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.85 - Yahoo Finance"

**4-2) Analyst Opinions:**

*   The analyst consensus leans towards a "Buy" rating (Mean = 1.90), with an average target price of $110.04. This suggests analysts, on average, expect the stock price to increase. However, it's important to consider the range of target prices ($83 - $139).

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-11-05 | 2.32 | 17.28 B$   |
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2025-11-05 | 1.25 | 16.66 B$   |

*   The most recent EPS (2.32) is higher than previous quarters, suggesting improved profitability. Revenue also shows a positive trend over the last few quarters. However, the table has duplicate value of 2025-11-05 with the same value of 2024-11-06.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

*   Both revenue and profit margins are generally increasing, indicating solid operational performance.

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $51.85B   | 11.16%    |
| 2025-06-30   | $48.99B   | 9.04%     |
| 2025-03-31   | $48.34B   | 10.51%    |
| 2024-12-31   | $46.31B   | 8.08%     |
| 2024-09-30   | $44.50B   | 7.09%     |

*   Equity and ROE (Return on Equity) also show a positive trend, suggesting increasing shareholder value.

**7) Comprehensive Analysis:**

Overall, the analysis presents a mixed picture for Merck & Co. (MRK).

**Positives:**

*   **Recent Upward Price Momentum:** The stock shows recent upward price momentum, supported by rising moving averages and some positive news.
*   **Solid Financials:** Revenue, profit margins, equity, and ROE all display a positive trend.
*   **Analyst Buy Consensus:** Analysts, on average, rate the stock as a "Buy".
*   **Dividend Increase:** Indicates confidence from the management in the company's future earnings.

**Negatives:**

*   **Significant Underperformance vs. S&P 500:** The stock has drastically underperformed the S&P 500 historically.
*   **Negative Alpha:** The negative alpha values indicate consistent underperformance relative to market benchmarks.
*   **High Volatility:** The high MDD figures and recently increasing Beta suggest significant volatility.
*   **Negative Expected Return:** The significantly negative expected return compared to the S&P 500 is a major concern.
*   **Overbought RSI:** The high RSI suggests a potential pullback.
*   **Conflicting MRI Signal:** The "High Investment Recommended" MRI rating contradicts other concerning indicators.

**Conclusion:**

While Merck shows some recent positive signs (price momentum, financial performance), the historical underperformance, negative expected return, and increasing volatility warrant caution. The "High Investment Recommended" MRI should be taken with a grain of salt given the numerous red flags. A prudent investor should conduct further due diligence and carefully consider their risk tolerance before investing in MRK. The recent surge in price may not be sustainable.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.